Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with CHOP or mini-CHOP in older adults with classical Hodgkin lymphoma
ACTRN12622000207718Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Aug 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of tislelizumab, doxorubicin, vincristine, cyclophosphamide and prednisone in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Complete metabolic response of tislelizumab lead-in and Deliverability of tislelizumab lead-in. Started Aug 2023; status: completed.
02
Drugs
tislelizumabdoxorubicinvincristinecyclophosphamideprednisone
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on ACTRN12622000207718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000207718.